Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Acute Heart Failure
NCT01800968Phase 2Completed
- Sponsor
- Duke University
- Start
- Apr 2013
- Primary completion
- Oct 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Global Ranking of Predefined Events at 180 days. Started Apr 2013; status: completed.
02
Drugs
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT01800968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01800968.